循环中M-MDSCs水平作为终末期恶性脑肿瘤患者BNCT治疗效果的指标

IF 2.1 Q3 ONCOLOGY
International Journal of Particle Therapy Pub Date : 2024-10-19 eCollection Date: 2024-12-01 DOI:10.1016/j.ijpt.2024.100633
Chun-Hsiang Chang, Ching-Fang Yu, Fang-Hsin Chen, Yi-Wei Chen, Chi-Shiun Chiang
{"title":"循环中M-MDSCs水平作为终末期恶性脑肿瘤患者BNCT治疗效果的指标","authors":"Chun-Hsiang Chang, Ching-Fang Yu, Fang-Hsin Chen, Yi-Wei Chen, Chi-Shiun Chiang","doi":"10.1016/j.ijpt.2024.100633","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Boron neutron capture therapy (BNCT) is a promising treatment modality for patients diagnosed with malignant brain tumors. It is currently used for emergency and compassionate purposes to treat end-stage malignant glioma or recurrent head and neck cancer patients in Taiwan. Understanding the factors influencing treatment response is crucial for optimizing patient care. This study aimed to investigate the association between tumor response and various parameters in end-stage malignant glioma patients following BNCT.</p><p><strong>Patients and methods: </strong>Fifteen patients with end-stage malignant brain tumors underwent a single fraction of BNCT. The treatment response was evaluated using cranial magnetic resonance imaging, and the association between treatment response and BNCT parameters was analyzed. Additionally, circulating myeloid-derived suppressor cell (MDSC) levels were measured by flow cytometry and correlated with patients' survival.</p><p><strong>Results: </strong>BNCT exhibited significant therapeutic efficacy in reducing tumor volume of these end-stage glioma patients, with 3 patients achieving complete response and 10 patients achieving partial response within 1 month, resulting in an impressive objective response rate of 80%. The median overall survival is 9 (1.77, 12.47) months, and the progression-free survival is 1.34 (0.53, 9.53) months. Kaplan-Meier analysis showed that the patients with complete response and partial response displayed better survival than those with stable disease. Treatment response was not significantly associated with initial tumor size, blood boron concentration, tumor-to-normal tissue ratio, or tumor-to-blood ratio. The ROC curve revealed a cut-off value of 5% of circulating M-MDSCs with a sensitivity of 66.67% and specificity of 73.33%, respectively, for predicting the glioma patient's response to BNCT.</p><p><strong>Conclusion: </strong>This clinical study demonstrates that BNCT can reduce tumor burden, improve disease control, and prolong survival in end-stage glioma patients. Circulating M-MDSCs may serve as a predictive indicator for the treatment response of these patients following BNCT.</p>","PeriodicalId":36923,"journal":{"name":"International Journal of Particle Therapy","volume":"14 ","pages":"100633"},"PeriodicalIF":2.1000,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11585706/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Level of Circulating M-MDSCs as an Indicator for the Therapeutic Outcome of BNCT in End-Stage Malignant Brain Tumor Patients.\",\"authors\":\"Chun-Hsiang Chang, Ching-Fang Yu, Fang-Hsin Chen, Yi-Wei Chen, Chi-Shiun Chiang\",\"doi\":\"10.1016/j.ijpt.2024.100633\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Boron neutron capture therapy (BNCT) is a promising treatment modality for patients diagnosed with malignant brain tumors. It is currently used for emergency and compassionate purposes to treat end-stage malignant glioma or recurrent head and neck cancer patients in Taiwan. Understanding the factors influencing treatment response is crucial for optimizing patient care. This study aimed to investigate the association between tumor response and various parameters in end-stage malignant glioma patients following BNCT.</p><p><strong>Patients and methods: </strong>Fifteen patients with end-stage malignant brain tumors underwent a single fraction of BNCT. The treatment response was evaluated using cranial magnetic resonance imaging, and the association between treatment response and BNCT parameters was analyzed. Additionally, circulating myeloid-derived suppressor cell (MDSC) levels were measured by flow cytometry and correlated with patients' survival.</p><p><strong>Results: </strong>BNCT exhibited significant therapeutic efficacy in reducing tumor volume of these end-stage glioma patients, with 3 patients achieving complete response and 10 patients achieving partial response within 1 month, resulting in an impressive objective response rate of 80%. The median overall survival is 9 (1.77, 12.47) months, and the progression-free survival is 1.34 (0.53, 9.53) months. Kaplan-Meier analysis showed that the patients with complete response and partial response displayed better survival than those with stable disease. Treatment response was not significantly associated with initial tumor size, blood boron concentration, tumor-to-normal tissue ratio, or tumor-to-blood ratio. The ROC curve revealed a cut-off value of 5% of circulating M-MDSCs with a sensitivity of 66.67% and specificity of 73.33%, respectively, for predicting the glioma patient's response to BNCT.</p><p><strong>Conclusion: </strong>This clinical study demonstrates that BNCT can reduce tumor burden, improve disease control, and prolong survival in end-stage glioma patients. Circulating M-MDSCs may serve as a predictive indicator for the treatment response of these patients following BNCT.</p>\",\"PeriodicalId\":36923,\"journal\":{\"name\":\"International Journal of Particle Therapy\",\"volume\":\"14 \",\"pages\":\"100633\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-10-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11585706/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Particle Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijpt.2024.100633\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Particle Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ijpt.2024.100633","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:硼中子俘获疗法(BNCT)是一种治疗恶性脑肿瘤患者的有效方法。在台湾,该疗法目前用于治疗恶性胶质瘤晚期或复发性头颈部癌症患者的急诊和恩恤治疗。了解影响治疗反应的因素对于优化患者护理至关重要。本研究旨在探讨BNCT治疗终末期恶性胶质瘤患者的肿瘤反应与各种参数之间的关系:15名终末期恶性脑肿瘤患者接受了单次BNCT治疗。使用头颅磁共振成像评估治疗反应,并分析治疗反应与 BNCT 参数之间的关联。此外,还通过流式细胞术测量了循环中髓源性抑制细胞(MDSC)的水平,并将其与患者的生存率进行了关联分析:结果:BNCT对缩小这些终末期胶质瘤患者的肿瘤体积有明显疗效,其中3名患者在1个月内获得完全反应,10名患者获得部分反应,客观反应率达到80%,令人印象深刻。中位总生存期为9(1.77,12.47)个月,无进展生存期为1.34(0.53,9.53)个月。卡普兰-梅耶尔分析显示,完全应答和部分应答患者的生存期优于病情稳定患者。治疗反应与初始肿瘤大小、血液硼浓度、肿瘤与正常组织比率或肿瘤与血液比率无明显关系。ROC曲线显示,循环M-MDSCs的临界值为5%时,预测胶质瘤患者对BNCT反应的灵敏度和特异度分别为66.67%和73.33%:这项临床研究表明,BNCT可以减轻终末期胶质瘤患者的肿瘤负荷,改善疾病控制,延长生存期。循环中的M-MDSCs可作为BNCT后这些患者治疗反应的预测指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Level of Circulating M-MDSCs as an Indicator for the Therapeutic Outcome of BNCT in End-Stage Malignant Brain Tumor Patients.

Purpose: Boron neutron capture therapy (BNCT) is a promising treatment modality for patients diagnosed with malignant brain tumors. It is currently used for emergency and compassionate purposes to treat end-stage malignant glioma or recurrent head and neck cancer patients in Taiwan. Understanding the factors influencing treatment response is crucial for optimizing patient care. This study aimed to investigate the association between tumor response and various parameters in end-stage malignant glioma patients following BNCT.

Patients and methods: Fifteen patients with end-stage malignant brain tumors underwent a single fraction of BNCT. The treatment response was evaluated using cranial magnetic resonance imaging, and the association between treatment response and BNCT parameters was analyzed. Additionally, circulating myeloid-derived suppressor cell (MDSC) levels were measured by flow cytometry and correlated with patients' survival.

Results: BNCT exhibited significant therapeutic efficacy in reducing tumor volume of these end-stage glioma patients, with 3 patients achieving complete response and 10 patients achieving partial response within 1 month, resulting in an impressive objective response rate of 80%. The median overall survival is 9 (1.77, 12.47) months, and the progression-free survival is 1.34 (0.53, 9.53) months. Kaplan-Meier analysis showed that the patients with complete response and partial response displayed better survival than those with stable disease. Treatment response was not significantly associated with initial tumor size, blood boron concentration, tumor-to-normal tissue ratio, or tumor-to-blood ratio. The ROC curve revealed a cut-off value of 5% of circulating M-MDSCs with a sensitivity of 66.67% and specificity of 73.33%, respectively, for predicting the glioma patient's response to BNCT.

Conclusion: This clinical study demonstrates that BNCT can reduce tumor burden, improve disease control, and prolong survival in end-stage glioma patients. Circulating M-MDSCs may serve as a predictive indicator for the treatment response of these patients following BNCT.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
International Journal of Particle Therapy
International Journal of Particle Therapy Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
3.70
自引率
5.90%
发文量
23
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信